2023 - Research.com Medicine in Belgium Leader Award
His primary areas of investigation include Internal medicine, Surgery, Gastroenterology, Pathology and Lymphoma. Internal medicine is closely attributed to Oncology in his research. His Oncology study combines topics in areas such as Refractory, Cytarabine, Survival rate, Immunology and Rituximab.
His work on Imatinib mesylate and Imatinib as part of general Immunology research is frequently linked to CXCR4, thereby connecting diverse disciplines of science. His Pathology study combines topics from a wide range of disciplines, such as Ex vivo, Hematology, Cytogenetics, Fluorescence in situ hybridization and Galactomannan. His research in Lymphoma focuses on subjects like Neutropenia, which are connected to Inotuzumab ozogamicin, Calicheamicin, Aspergillosis, Mycosis and Pharmacology.
Gregor Verhoef mainly investigates Internal medicine, Pathology, Oncology, Lymphoma and Immunology. His Internal medicine research includes themes of Gastroenterology and Surgery. In his study, which falls under the umbrella issue of Pathology, Karyotype is strongly linked to Cytogenetics.
The various areas that Gregor Verhoef examines in his Oncology study include Cytarabine, Myeloid leukemia, Refractory and Phases of clinical research. His Lymphoma study integrates concerns from other disciplines, such as Positron emission tomography, Nuclear medicine, Cancer research and Survival analysis. His Rituximab research includes elements of Vincristine and Mantle cell lymphoma.
His scientific interests lie mostly in Internal medicine, Lymphoma, Rituximab, Cancer research and Oncology. His work carried out in the field of Internal medicine brings together such families of science as Gastroenterology and Surgery. Lymphoma is a subfield of Pathology that Gregor Verhoef tackles.
His studies in Rituximab integrate themes in fields like CHOP, Vincristine, Mantle cell lymphoma and Prednisone. As part of one scientific family, he deals mainly with the area of Oncology, narrowing it down to issues related to the Open label, and often B-Cell Non-Hodgkin Lymphoma. His work in Chemotherapy addresses issues such as Immunology, which are connected to fields such as Stem cell.
Internal medicine, Lymphoma, Oncology, Rituximab and Gastroenterology are his primary areas of study. Many of his studies involve connections with topics such as Surgery and Internal medicine. His studies deal with areas such as Cancer research, Comparative genomic hybridization and Single Center as well as Lymphoma.
He has researched Oncology in several fields, including Post transplant, Cohort study and Chemotherapy. The Rituximab study combines topics in areas such as CHOP, Vincristine and Transplantation. His Gastroenterology study also includes fields such as
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia
Stephen G. O'Brien;François Guilhot;Richard A. Larson;Insa Gathmann.
The New England Journal of Medicine (2003)
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
Brian J. Druker;François Guilhot;Stephen G. O'brien;Insa Gathmann.
The New England Journal of Medicine (2006)
A Tyrosine Kinase Created by Fusion of the PDGFRA and FIP1L1 Genes as a Therapeutic Target of Imatinib in Idiopathic Hypereosinophilic Syndrome
Jan Cools;Jan Cools;Daniel J. DeAngelo;Jason Gotlib;Elizabeth H. Stover.
The New England Journal of Medicine (2003)
Stromal gene signatures in large-B-cell lymphomas
G Lenz;G Wright;S S Dave;W Xiao.
The New England Journal of Medicine (2008)
High-dose daunorubicin in older patients with acute myeloid leukemia.
Bob Löwenberg;Gert J. Ossenkoppele;Wim van Putten;Harry C. Schouten.
The New England Journal of Medicine (2009)
Acquired mutations in TET2 are common in myelodysplastic syndromes
Saskia M C Langemeijer;Roland P Kuiper;Marieke Berends;Ruth Knops.
Nature Genetics (2009)
Low-Dose 5-Aza-2′-Deoxycytidine, a DNA Hypomethylating Agent, for the Treatment of High-Risk Myelodysplastic Syndrome: A Multicenter Phase II Study in Elderly Patients
P Wijermans;M Lübbert;Gregor Verhoef;A Bosly.
Journal of Clinical Oncology (2000)
Galactomannan and Computed Tomography–Based Preemptive Antifungal Therapy in Neutropenic Patients at High Risk for Invasive Fungal Infection: A Prospective Feasibility Study
Johan Maertens;Koen Theunissen;Gregor Verhoef;Johnny Verschakelen.
Clinical Infectious Diseases (2005)
ALK+ Lymphoma: Clinico-Pathological Findings and Outcome
Brunangelo Falini;Stefano Pileri;Pier Luigi Zinzani;Antonino Carbone.
Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
Georg Hess;Raoul Herbrecht;Jorge Romaguera;Gregor Verhoef.
Journal of Clinical Oncology (2009)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: